The metastatic prostate cancer market is shifting from traditional hormone therapies to precision, biomarker-driven treatments, including novel PARP inhibitors and PSMA-targeted radioligand therapies. The market, valued at $11.5 billion in 2025 in major markets like the US and EU, is expected to expand significantly due to rising prostate cancer cases, improved diagnostics, and a robust pipeline of innovative drugs from leading pharma companies. Upcoming therapies such as 225Ac-PSMA-617, 177Lu-DOTA-rosopatamab, and Mevrometostat are poised to reshape treatment standards and drive market growth through 2036.
Ahead of its mega-IPO, SpaceX revealed healthcare ambitions in its SEC filing, highlighting Starlink's role in improving remote healthcare access in underserved areas. The company also envisions manufacturing pharmaceuticals in orbit, leveraging micr...
Novartis will showcase results from multiple clinical trials of Rhapsido (remibrutinib) at the EAACI Congress 2026, including pivotal Phase III data for chronic inducible urticaria and extension data for chronic spontaneous urticaria. The presentatio...
This monthly series highlights five large-cap, dividend-paying stocks trading at significant discounts compared to their historical norms, selected from over 7,500 U.S.-listed companies. The primary list offers an average yield of 4.2%, with two addi...
